22:41 , Sep 13, 2018 |  BC Week In Review  |  Clinical News

4D's MRx0004 improves inflammation in asthma model

4D Pharma plc (LSE:DDDD) said once-daily oral MRx0004 protected against airway inflammation by decreasing infiltration of both neutrophils and eosinophils in the lung bronchoalveolar lavage fluid of a house dust mite mouse model of severe...
02:35 , Jul 15, 2017 |  BioCentury  |  Finance

Guts and ambition

With an additional $50 million in funding and plans to start 5-10 clinical trials of monoclonal microbials in 2018, Evelo Biosciences Inc. is shaping up to be one of the most ambitious of the microbiome...
22:39 , Apr 7, 2017 |  BioCentury  |  Finance

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...
00:30 , Jan 13, 2017 |  BC Innovations  |  Targets & Mechanisms

Gut control

As evidence mounts linking obesity to the microbiome, three independent studies have identified separate ways of harnessing gut microbiota to treat the condition. The spectrum of approaches, which involve a bacterial protein, a bacterial species...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Thetanix: Phase I started

4D Pharma began a double-blind, placebo-controlled, U.K. Phase I trial to evaluate oral Thetanix in about 20 patients ages 16-18. In the first part, 10 patients will receive a single dose of Thetanix. In the...
07:00 , May 9, 2016 |  BioCentury  |  Product Development

Community organizers

With new papers published by the day and a flurry of big-dollar deals and financings, it's hard to separate the signal from the noise in the microbiome space. The space has become so hot that...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

Blautix: Completed Phase I enrollment

4D completed enrollment of 56 healthy volunteers and patients in a Phase I trial of Blautix. 4D Pharma plc (LSE:DDDD), Manchester, U.K.   Product: Blautix   Business: Gastrointestinal   Molecular target: NA   Description: Live biotherapeutic   Indication: Treat...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Company News

Tucana, 4D Pharma deal

4D acquired microbiome company Tucana in a stock deal for 410,603 shares of 4D, valued at L3.1 million ($4.5 million) based on 4D’s close of 755p on Feb. 9, the day before the deal was...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Financial News

4D Pharma completes placing

4D Pharma plc (LSE:DDDD), Manchester, U.K.   Business: Autoimmune   Date completed: 2015-12-08   Type: Placing   Raised: L30 million ($45.2 million)   Shares: 3.8 million   Price: 790p   Shares after offering: 64.4 million   Placement agent: Zeus Capital   Investors: Invesco; Woodford...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Company News

4D Pharma, University College Cork deal

4D partnered with the university’s APC Microbiome Institute to research live biotherapeutics to treat autism and associated CNS disorders. Under the EUR4.8 million ($5.4 million), four-year deal, the partners will use 4D’s MicroRx platform, which...